Major Institutional Investors Reduce Valneva Stake After Not Participating in €84M Offering
summarizeSummary
Major institutional investors Bpifrance and Caisse des Depots updated their Schedule 13D, reporting a diluted stake after not participating in Valneva's recent €84 million offering and detailing net share sales totaling approximately $2.14 million.
check_boxKey Events
-
Dilution from Reserved Offering
The reporting persons (Bpifrance and Caisse des Depots) did not participate in Valneva's recent €84 million reserved offering, which resulted in a dilution of their ownership percentages.
-
Bpifrance Participations Sells Shares
Bpifrance Participations S.A. sold 356,003 ordinary shares for approximately €1.76 million in open market transactions during March 2026.
-
CDC Croissance Net Sales
CDC Croissance S.A. acquired 130,000 ordinary shares for approximately €0.59 million and sold 289,645 ordinary shares for approximately €0.81 million in March 2026, resulting in net sales of approximately €0.22 million.
-
Updated Ownership Stake
As of May 5, 2026, Bpifrance Participations holds 7.0% of voting rights, and Caisse des Depots et consignations holds 9.3% of voting rights, reflecting the impact of the offering and recent transactions.
auto_awesomeAnalysis
This Schedule 13D/A updates the holdings of major institutional investors, Bpifrance and Caisse des Depots, following Valneva's recent €84 million reserved offering. These investors chose not to participate in the offering, resulting in a dilution of their ownership percentages. Additionally, the filing details recent open market transactions, including Bpifrance Participations selling approximately €1.76 million worth of shares and CDC Croissance making net sales of approximately €0.22 million. This indicates a reduction in their overall stake, both actively through sales and passively through non-participation in the capital raise.
At the time of this filing, VALN was trading at $6.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $611.8M. The 52-week trading range was $5.06 to $12.25. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.